CD274 and neoplasm: The potential clinical value of tumoral PD-L1 expression in EC patients with residual disease after nCRT with surgery has shown to be significant for DFS after adjuvant anti-PD-1 nivolumab in the Checkmate-577 study, and showed a better PR in the Keynote-590 study with anti-PD-1 pembrolizumab and nCRT.3,7 The included studies also showed that a high proportion of PD-L1 in positive treatment-naïve tumor samples may affect PR; however, the exact mechanism behind this is still unknown.